Department of Radiotherapy, Policlinico Umberto I, "Sapienza" University of Rome, Rome, Italy.
Department of Gynecological and Obstetrical Sciences and Urological Sciences, "Sapienza" University of Rome, Rome, Italy.
Cancer Treat Rev. 2017 Dec;61:1-5. doi: 10.1016/j.ctrv.2017.09.005. Epub 2017 Sep 28.
This review is focused on the ovarian cancer risk reduction management in BRCA mutation carriers and is intended to assist with clinical decision-making. Obviously, treatment decisions must be based on the available evidence. Despite risk-reducing salpingo-oophorectomy is firmly recommended, several separate questions can be raised to address the variety of intense controversy of this approach. A special emphasis lies in the effective preventive surgical measure against ovarian cancer risk, in an attempt to detect the optimal timing and mitigate the impact on patients. The long term implications of risk-reducing salpingo-oophorectomy as well as hormone replacement therapy are also actively debated. This is expected to represent an opportunity for improved management modelling of BRCA mutated patients.
本综述重点关注 BRCA 基因突变携带者的卵巢癌风险降低管理，旨在为临床决策提供帮助。显然，治疗决策必须基于现有证据。尽管强烈推荐进行预防性输卵管卵巢切除术，但仍有几个单独的问题需要提出，以解决这种方法存在的各种争议。特别强调的是，针对卵巢癌风险的有效预防性手术措施，试图确定最佳时机并减轻对患者的影响。预防性输卵管卵巢切除术和激素替代疗法的长期影响也在积极争论中。这有望为改善 BRCA 突变患者的管理模式提供机会。
